Catalyst Pharmaceuticals (CPRX) Change in Accured Expenses (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly Change in Accured Expenses of -$9.2 million for Q1 2026, down 260.78% year-on-year from $5.7 million in Q1 2025, and down 276.72% on a QoQ basis from $5.2 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 17 years of Change in Accured Expenses data on file, last reported at -$9.2 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 260.78% year-over-year to -$9.2 million; the trailing twelve-month figure through Mar 2026 stood at $17.5 million (down 59.11% YoY), and the FY2025 full-year result was $24.2 million, down 55.13% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$9.2 million, down from $5.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $20.0 million in Q3 2024 and bottomed at -$9.2 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is $8.2 million (2023), against an average of $5.4 million.
- The widest annual swing landed in 2023, when Change in Accured Expenses slumped 316.77%; it then jumped 449.88% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $11.5 million in 2022, then fell by 28.82% to $8.2 million in 2023, then gained by 8.67% to $8.9 million in 2024, then sank by 41.46% to $5.2 million in 2025, then sank by 276.72% to -$9.2 million in 2026.
- The last three Change in Accured Expenses figures came in at -$9.2 million (Q1 2026), $5.2 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | -9.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.21 Mn |
| Mar 31, 2026 | -9.21 Mn |
| Dec 31, 2025 | 5.21 Mn |
| Dec 31, 2025 | 5.21 Mn |
| Sep 30, 2025 | 13.24 Mn |
| Sep 30, 2025 | 13.24 Mn |
| Jun 30, 2025 | 8.27 Mn |
| Jun 30, 2025 | 8.27 Mn |
| Mar 31, 2025 | -2.55 Mn |
| Mar 31, 2025 | -2.55 Mn |
| Dec 31, 2024 | 8.90 Mn |
| Dec 31, 2024 | 8.90 Mn |
| Sep 30, 2024 | 20.05 Mn |
| Sep 30, 2024 | 20.05 Mn |
| Jun 30, 2024 | 16.43 Mn |
| Jun 30, 2024 | 16.43 Mn |
| Mar 31, 2024 | 8.47 Mn |
| Mar 31, 2024 | 8.47 Mn |
| Dec 31, 2023 | 8.19 Mn |
| Dec 31, 2023 | 8.19 Mn |
| Sep 30, 2023 | 5.16 Mn |
| Sep 30, 2023 | 5.16 Mn |
| Jun 30, 2023 | -5.13 Mn |
| Jun 30, 2023 | -5.13 Mn |
| Mar 31, 2023 | -2.42 Mn |
| Mar 31, 2023 | -2.42 Mn |
| Dec 31, 2022 | 11.51 Mn |
| Dec 31, 2022 | 11.51 Mn |
| Sep 30, 2022 | 9.02 Mn |
| Sep 30, 2022 | 9.02 Mn |
| Jun 30, 2022 | 2.37 Mn |
| Jun 30, 2022 | 2.37 Mn |
| Mar 31, 2022 | -6.50 Mn |
| Mar 31, 2022 | -6.50 Mn |
| Dec 31, 2021 | 6.44 Mn |
| Dec 31, 2021 | 6.44 Mn |
| Sep 30, 2021 | 4.57 Mn |
| Sep 30, 2021 | 4.57 Mn |
| Jun 30, 2021 | 1.55 Mn |
| Jun 30, 2021 | 1.55 Mn |
| Mar 31, 2021 | -7.04 Mn |
| Mar 31, 2021 | -7.04 Mn |
| Dec 31, 2020 | 2.36 Mn |
| Dec 31, 2020 | 2.36 Mn |
| Sep 30, 2020 | 1.90 Mn |
| Sep 30, 2020 | 1.90 Mn |
| Jun 30, 2020 | -1.77 Mn |
| Jun 30, 2020 | -1.77 Mn |
| Mar 31, 2020 | -3.70 Mn |
| Mar 31, 2020 | -3.70 Mn |
| Dec 31, 2019 | 6.14 Mn |
| Dec 31, 2019 | 6.14 Mn |
| Sep 30, 2019 | 3.01 Mn |
| Sep 30, 2019 | 3.01 Mn |
| Jun 30, 2019 | 4.73 Mn |
| Jun 30, 2019 | 4.73 Mn |
| Mar 31, 2019 | -1.34 Mn |
| Mar 31, 2019 | -1.34 Mn |
| Dec 31, 2018 | 5.04 Mn |
| Dec 31, 2018 | 5.04 Mn |
| Sep 30, 2018 | -10,539.00 |
| Sep 30, 2018 | -10,539.00 |
| Jun 30, 2018 | 226,004.00 |
| Jun 30, 2018 | 226,004.00 |
| Mar 31, 2018 | -401,277.00 |
| Mar 31, 2018 | -401,277.00 |
| Dec 31, 2017 | 664,671.00 |
| Dec 31, 2017 | 664,671.00 |
| Sep 30, 2017 | 501,902.00 |
| Sep 30, 2017 | 501,902.00 |
| Jun 30, 2017 | 154,996.00 |
| Jun 30, 2017 | 154,996.00 |
| Mar 31, 2017 | -178,917.00 |
| Mar 31, 2017 | -178,917.00 |
| Dec 31, 2016 | 217,155.00 |
| Dec 31, 2016 | 217,155.00 |
| Sep 30, 2016 | -660,831.00 |
| Sep 30, 2016 | -660,831.00 |
| Jun 30, 2016 | 183,412.00 |
| Jun 30, 2016 | 183,412.00 |
| Mar 31, 2016 | -219,984.00 |
| Mar 31, 2016 | -219,984.00 |
| Dec 31, 2015 | 124,718.00 |
| Dec 31, 2015 | 124,718.00 |
| Sep 30, 2015 | 317,468.00 |
| Sep 30, 2015 | 317,468.00 |
| Jun 30, 2015 | -63,231.00 |
| Jun 30, 2015 | -63,231.00 |
| Mar 31, 2015 | 755,984.00 |
| Mar 31, 2015 | 755,984.00 |
| Dec 31, 2014 | -1.37 Mn |
| Dec 31, 2014 | -1.37 Mn |
| Sep 30, 2014 | 4.29 Mn |
| Sep 30, 2014 | 4.29 Mn |
| Jun 30, 2014 | -385,354.00 |
| Jun 30, 2014 | -385,354.00 |
| Mar 31, 2014 | 214,681.00 |
| Mar 31, 2014 | 214,681.00 |
| Dec 31, 2013 | -250,409.00 |
| Dec 31, 2013 | -250,409.00 |
| Sep 30, 2013 | 348,316.00 |
| Sep 30, 2013 | 348,316.00 |
| Jun 30, 2013 | 772,728.00 |
| Jun 30, 2013 | 772,728.00 |
| Mar 31, 2013 | 134,436.00 |
| Mar 31, 2013 | 134,436.00 |
| Dec 31, 2012 | -116,826.00 |
| Dec 31, 2012 | -116,826.00 |
| Sep 30, 2012 | -56,357.00 |
| Sep 30, 2012 | -56,357.00 |
| Jun 30, 2012 | -74,744.00 |
| Jun 30, 2012 | -74,744.00 |
| Mar 31, 2012 | -28,578.00 |
| Mar 31, 2012 | -28,578.00 |
| Dec 31, 2011 | 330,769.00 |
| Dec 31, 2011 | 330,769.00 |
| Sep 30, 2011 | 70,491.00 |
| Sep 30, 2011 | 70,491.00 |
| Jun 30, 2011 | -269,531.00 |
| Jun 30, 2011 | -269,531.00 |
| Mar 31, 2011 | 234,052.00 |
| Mar 31, 2011 | 234,052.00 |
| Dec 31, 2010 | 34,210.00 |
| Dec 31, 2010 | 34,210.00 |
| Sep 30, 2010 | -73,028.00 |
| Sep 30, 2010 | -73,028.00 |